logo

INBS

Intelligent Bio·NASDAQ
--
--(--)
--
--(--)
1.06 / 10
Underperform

Fundamental measurement shows subpar quality (1.1/10). Constructive metrics: Asset-MV and Net profit attributable to parent company shareholders / Net profit (%), with caution warranted for Revenue-MV and Net income-Revenue. Final assessment: guarded.

Fundamental(1.06)SentimentTechnical

Analysis Checks(4/10)

Revenue-MV
Value-0.79
Score0/3
Weight12.73%
1M Return-3.84%
ROA (%)
Value-96.28
Score0/3
Weight17.36%
1M Return-7.78%
Net profit attributable to parent company shareholders / Net profit (%)
Value99.66
Score2/3
Weight5.83%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight8.23%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight14.22%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-96.28
Score0/3
Weight17.36%
1M Return-7.78%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight6.57%
1M Return-1.95%
Asset-MV
Value-0.98
Score2/3
Weight-6.84%
1M Return1.60%
Cash-MV
Value-0.07
Score1/3
Weight15.62%
1M Return-5.64%
Net profit / Total profit (%)
Value100.00
Score1/3
Weight8.92%
1M Return-2.89%
Is INBS fundamentally strong?
  • INBS scores 1.06/10 on fundamentals and holds a Premium valuation at present. Backed by its -95.60% ROE, -265.40% net margin, -0.72 P/E ratio, 2.21 P/B ratio, and -1733.33% earnings growth, these metrics solidify its Underperform investment rating.